| abstract |
The pharmaceutical preparations for treating side effects, such as hot flashes, prostate enlargement and gynecomastia, during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone (GnRHa therapy) contain an effective amount of a chemically modified derivative of 17α-estradiol, a chemically modified derivative of 17β-estradiol and/or a chemical modified derivative of estriol. Pharmaceutical preparations containing 14α, 15α-methylene-1,3,5(10),8-tetraene-3,17α-diol are particularly preferred. |